Pharmaceutical company Allergan has acquired all assets of biotechnology company RetroSense Therapeutics through an all-cash transaction worth $60m.
According to the agreement, Allergan will be responsible to pay potential regulatory and milestone-based payments to RetroSense.
The acquisition enables Allergan to further advance its ongoing development programmes for critical diseases.
Asahi Glass plans to expand its business through its recent acquisition of contract manufacturing company Biomeva.
The target company is a subsidiary of Biomeva Holding that manufactures and distributes biologics, active pharmaceutical ingredients (APIs) and therapeutic proteins, while the acquirer is a glass company based in Japan.
Image: Allergan has acquired RetroSense Therapeutics. Photo: courtesy of Coolcaesar at the English language Wikipedia.
